UK pharma: 25 years of innovation and controversy
Whitefriars’ Ketan Patel discusses what investors need to consider when investing in the pharmaceutical sector
Pharmaceuticals
-
-
Q&A: Vontobel’s Frontczak on medical aid, Ozempic and healthcare innovation
Vontobel’s Joanna Frontczak is an analyst on the firm’s global impact equities fund
-
Making gender visible: A path to systemic inclusion
As companies abandon efforts to promote inclusion, Boston Common’s Geeta Aiyer urges investors to keep it a top priority
-
Why Wheb AM has increased exposure to big pharma
Previously a no-go area, the firm has developed a drug pricing checklist
-
Health needs to be part of the conversation about investments in nature
GSK’s VP of sustainability writes exclusively for ESG Clarity on the health benefits of investing in nature
-
Pharmaceuticals remain a draw for ESG investors
EdenTree’s Patel says industry’s response to Covid and innovation keep it attractive to ESG investors
-
Healthcare scores poorly for ESG but is a vital sector
Access to medicine as well as litigation and reputation risks make it a complex area for sustainable investors
-
Healthcare scores poorly for ESG but is a vital sector
Access to medicine as well as litigation and reputation risks make it a complex area for sustainable investors
-
Sector special: Healthcare poses challenges for ESG investors
Access to medicine as well as litigation risks and reputation make it a complex area
-
Gap takes BlackRock’s top spot as most diverse firm
Refinitiv’s annual index shows diversity and inclusion progress stalled in some areas despite it rising up the agenda
-
Investors should consider biodiversity and pharma this Earth Day
As much as 50% of prescription drugs are based on a molecule that occurs naturally in a plant
-
The UK’s income stream is turning green
Whether it be energy, pharmaceuticals or industrials, businesses are focusing on sustainable future income streams, R&M’s Dan Hanbury tells ESG Clarity